AI-generated illustration; not a photograph of the reported event.
- calendar_today October 7, 2026
Trump Touts Drug Pricing Success Ahead of Midterms
In the lead-up to the Nov. 3 midterm elections, President Donald Trump has promoted his administration’s progress on lowering prescription drug costs, emphasizing the TrumpRx.gov program as delivering the lowest drug prices globally. "This one thing alone should win us the midterms," Trump stated at a recent White House event. Since launching in February, TrumpRx.gov expanded from a small selection to offering discounts on over 800 brand-name and generic medications.
Evaluating TrumpRx's Actual Discounts
While Trump has claimed Americans now pay the world’s lowest prescription drug prices, recent analysis reveals that the reality is more nuanced. The TrumpRx site uses pricing data and technology from GoodRx and blends manufacturer-offered discounts with newly negotiated prices. However, according to federal inflation data, prescription drug prices fell 3.1% year-over-year as of July, but experts say it is too early to determine the direct impact of Trump’s drug pricing initiatives.
Drug Pricing Analysis: KFF Findings
A report from KFF, a nonpartisan research organization, assessed TrumpRx prices for 32 brand-name drugs without generic or biosimilar equivalents, comparing them to costs in 11 wealthy countries including the UK, France, Germany, the Netherlands, and Canada. The drugs chosen have greater potential impact because patients cannot switch to cheaper alternatives.
The analysis found:
- For 17 drugs, TrumpRx prices were lower than the average price abroad.
- For 15 drugs, TrumpRx prices were higher.
- Only 5 of 32 drugs were actually the lowest-priced globally.
- 13 drugs were more expensive on TrumpRx than in any comparison country.
For example, Ozempic costs $349 via TrumpRx for out-of-pocket users, compared to $190 per month in many other wealthy nations. Enbrel, a rheumatoid arthritis drug, is $3,354 per month on TrumpRx, over five times the $641 average abroad. Yet, Rydapt, a blood cancer medication, costs $2,909 for 56 capsules through TrumpRx—less than half the $5,901 price in France.
President Trump's Claims Versus Global Prices
Trump has asserted that, "We went from the highest prescription drug prices, by far, anywhere in the world, to the lowest prescription drug prices anywhere in the world.” However, KFF's deputy director Juliette Cubanski described the results as "a mixed bag," with discounts not consistently producing the lowest global prices, even after negotiations. Dr. Benjamin Rome of Harvard Medical School commented that TrumpRx covered a limited selection of drugs and the discounts were not always tied to international pricing trends.
Limits and Complexities of Drug Price Comparison
Direct comparison of drug prices can be challenging. The analysis did not cover every medication on TrumpRx.gov, and discrepancies in product availability between countries further complicate price matching. Antonio Ciaccia of 46brooklyn Research noted the U.S. market offers more drug options than some international systems, and confidential discounts abroad may not be reflected in public data.
TrumpRx operates as a platform directing consumers to manufacturer programs for coupons or cash discounts—not as a direct pharmacy. This system does not apply to most Americans, about 90% of whom access medications via insurance plans, and such out-of-pocket discounts usually don’t count toward insurance deductibles or copays.
Looking Ahead: Potential for U.S. Drug Price Reductions
The White House credits Trump’s "most favored nation" approach—seeking the same low prices drug makers offer other countries, in exchange for tariff relief—for the discounts. Trump claims deals with 26 major pharmaceutical companies have achieved discounts of 60% or more. Yet, health policy experts caution that broad, long-term impacts on U.S. drug pricing remain unclear, and future price shifts abroad could affect comparisons.
In summary, while TrumpRx provides medication cost discounts in some cases, Trump’s assertion that the U.S. now boasts the world’s lowest drug prices is not consistently supported by international drug prices and current drug price comparisons. The landscape for healthcare drug savings through drug manufacturer agreements remains dynamic and under review.
